Overview
David Rosenbloom is co-counsel for Amgen Inc. in a Second Circuit lawsuit by a whistleblower claiming that the company’s anemia biologic Epogen does not promote patient quality of life. Amgen’s defense noted that Epogen has always been approved by the FDA as an anemia treatment and the whistleblower’s allegations about quality of life aren’t relevant to those uses.